ANTIGISTAMINNYE PREPARATY V LEChENII ALLERGIChESKIKh ZABOLEVANIY U DETEY: FOKUS NA DEZLORATADIN PRI ALLERGIChESKOM RINITE

The article presents the modern data on the prevalence of allergic rhinitis in adults and children. There is often combination of AR and atopic bronchial asthma (BA), because of their shared pathogenesis. The main goal of pharmacological treatment of AR is a 24-hour control of symptoms with a single daily dose of the drug. This will achieved by using second-generation antihistamines, and the most preferred drug is desloratadine (Aerius), a primary active metabolite of loratadine. Desloratadine is characterized by a similar pharmacodynamic properties with loratadine, but the activity exceeds the latter and other drugs in this group in the 2.5-4.0 times. Desloratadine has additional anti-allergic effects unrelated to the blockade of Hl-histamine receptor: inhibition of expression of adhesion molecules, production and release of inflammatory mediators and cytokines, eosinophil chemotaxis factors. Along with the high efficiency, desloratadine is characterized by high safety. Taking into account the fact that desloratadine does not cause sedation, does not affect attention, memory, motor coordination and learning ability, it may be the drug of first choice for school-age children. The severity of AR and BA is closely related; therefore, adequate treatment of AR leads to an improvement of course of BA, improving quality of life of children.

allergic rhinitis, bronchial asthma, antihistamines, desloratadine, Aerius